猪失血性休克模型中氨甲环酸肌内注射与静脉输注的药代动力学比较
该研究在12头约克夏杂交猪中建立35%控制性失血性休克模型,随机给予1 g静脉氨甲环酸输注10分钟、1 g肌内氨甲环酸分两次5 mL注射或10 mL生理盐水肌内注射安慰剂。结果显示两种给药途径的浓度-时间曲线下面积无差异,肌内氨甲环酸绝对生物利用度为97%,静脉给药仅在输注期间血药浓度峰值更高,之后无差异。两种途径均完全逆转体外tPA诱导的高纤溶。作者认为,在难以建立专用静脉通路时,肌内氨甲环酸可能有益。
要点
- 在猪失血性休克模型中,肌内注射1 g氨甲环酸与静脉输注1 g的浓度-时间曲线下面积无差异,绝对生物利用度为97%。
- 静脉输注氨甲环酸仅在10分钟输注期间血药浓度峰值更高,输注后与肌内注射无差异。
- 静脉与肌内注射氨甲环酸均完全逆转体外tPA诱导的高纤溶。
- 作者认为,在难以建立专用静脉通路可能限制或延迟氨甲环酸使用时,肌内注射氨甲环酸可能有益。
适用人群与场景
- 12头约克夏杂交猪,麻醉后行35%控制性失血并复苏,达到III级休克。
处置流程与药物剂量
- 静脉组:1 g氨甲环酸静脉输注10分钟。
- 肌内组:1 g氨甲环酸分两次5 mL肌内注射。
- 安慰剂组:10 mL生理盐水肌内注射。
研究设计与关键结果
- 研究类型:动物实验(猪失血性休克模型),样本量12头。
- 两组氨甲环酸给药途径的浓度-时间曲线下面积无差异。
- 肌内氨甲环酸绝对生物利用度为97%。
- 静脉氨甲环酸在输注期间血药浓度峰值更高,后续无差异。
- 静脉与肌内氨甲环酸均完全逆转体外tPA诱导的高纤溶。
证据类型、等级与局限
- 证据类型:动物实验(猪模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在难以建立专用静脉通路可能限制或延迟氨甲环酸使用的场景中,肌内注射氨甲环酸可能有益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Tranexamic acid (TXA) improves survival in traumatic hemorrhage, but difficulty obtaining intravenous (IV) access may limit its use in austere environments, given its incompatibility with blood products. The bioavailability of intramuscular (IM) TXA in a shock state is unknown. We hypothesized that IM and IV administration have similar pharmacokinetics and ability to reverse in vitro hyperfibrinolysis in a swine-controlled hemorrhage model.
METHODS: Twelve Yorkshire cross swine were anesthetized, instrumented, and subjected to a 35% controlled hemorrhage, followed by resuscitation. During hemorrhage, they were randomized to receive a 1 g IV TXA infusion over 10 min, 1 g IM TXA in two 5 mL injections, or 10 mL normal saline IM injection as a placebo group to assess model adequacy. Serum TXA concentrations were determined using liquid chromatography-mass spectrometry, and plasma samples supplemented with tissue plasminogen activator (tPA) were analyzed by rotational thromboelastometry.
RESULTS: All animals achieved class III shock. There was no difference in the concentration-time areas under the curve between TXA given by either route. The absolute bioavailability of IM TXA was 97%. IV TXA resulted in a higher peak serum concentration during the infusion, with no subsequent differences. Both IV and IM TXA administration caused complete reversal of in vitro tPA-induced hyperfibrinolysis.
CONCLUSION: The pharmacokinetics of IM TXA were similar to IV TXA during hemorrhagic shock in our swine model. IV administration resulted in a higher serum concentration only during the infusion, but all levels were able to successfully correct in vitro hyperfibrinolysis. There was no difference in total body exposure to equal doses of TXA between the two routes of administration. IM TXA may prove beneficial in scenarios where difficulty establishing dedicated IV access could otherwise limit or delay its use.
参考来源
- Spruce MW, Beyer CA, Caples CM, et al. Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage. Shock. 2020. PMID: 31389905. doi:10.1097/SHK.0000000000001427
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。